Heparin sodium for Skin

Besides An Essential Skin Care Ingredient, Heparin sodium Can Do More!

• 2020-07-27
  

  Supply and demand status/development trend of China's heparin sodium industry

  Heparin sodium is an anticoagulant (blood thinner) that prevents thrombosis. With the acceleration of the pace of life and the increase of population aging, the global morbidity and mortality of cardiovascular and cerebrovascular diseases are increasing year by year. Heparin sodium is an effective way to solve these diseases. Heparin sodium raw material can be directly used to produce unfractionated heparin preparations, or it can be used to produce low molecular weight heparin sodium raw materials and then low molecular heparin preparations. Both unfractionated heparin preparations and low-molecular-weight heparin preparations belong to heparin drugs and are commonly used clinical anticoagulants. They are widely used in hemodialysis and various surgical operations. They are also clinically used to treat venous thrombosis and acute coronary syndrome ( Angina pectoris, myocardial infarction) and other diseases.Supply: companies and output tend to riseFrom the perspective of the number of heparin sodium companies, according to the data from the company's cat investigation, the number of companies related to heparin sodium in the country has increased overall from 2015 to 2020, reaching 89 in 2019, an increase of 14 from 2018.In terms of market heparin sodium production and sales supply, take Dongcheng Pharmaceutical, a typical enterprise in the heparin sodium industry, as an example. From 2011 to 2019, Dongcheng Pharmaceutical's heparin sodium production and sales have continued to rise in the past three years. In 2019, the output reached 2,930.235 billion units, an increase of 46 year-on-year. %, a significant increase; sales volume reached 2363.043 billion units, a year-on-year increase of 17%.Demand: continuous growthIn terms of market demand, heparin sodium has anticoagulant effects and is widely used in hemodialysis and various surgical operations. According to the National Bureau of Statistics, the number of inpatient operations in medical and health institutions continued to increase from 2011 to 2019, reaching 61,715,800 in 2018, a year-on-year increase of 10%, and it is initially estimated to increase to 67.59 million in 2019.In addition, heparin sodium is clinically used for diseases such as ischemic heart disease and angina pectoris. Based on the proportion of discharged patients with angina pectoris, it can be understood that the number of patients with this type of disease may increase. The proportion of discharged patients with angina pectoris continues to rise from 2011 to 2019, reaching 1.35% in 2018, an increase of 0.18 percentage points from 2017, preliminary estimates It reached 1.57% in 2019, indicating that market demand has expanded.Price: The sales price of heparin sodium has risen significantlyChanges in the supply and demand of heparin sodium affect market prices. Take the export situation of heparin and its salts (30019010) as an example. As the epidemic spreads globally, the price of heparin sodium will rise sharply in 2020. From 2017 to 2019, the export value of heparin and its salt increased significantly, reaching 761.28 million yuan in 2019, and the export volume reached 2.01 million tons; according to the export volume and export value of heparin and its salt, the average price of heparin sodium from January to May 2020 is 5817 10,000 CNY/ton, an increase of 54% from the average price in 2019, a significant increase.
  heparin sodium demand&supply Pharmaceutical
• 2023-12-15
  

  China's Active Pharmaceutical Ingredients Industry Analysis - The Thriving World of Active Pharmaceutical Ingredients: Exploring the Dynamic Landscape

  Nanjing Kingfriend Pharma (Stock Code: 603707) is a company focused on the field of biopharmaceuticals. Established in 2000, it was formerly known as Nanjing Second Biochemical Pharmaceutical Factory. Nanjing Kingfriend Pharma is one of the early pharmaceutical companies in China engaged in heparin extraction, purification, and the development of structural confirmation methods for heparin-like polysaccharide products. The company is currently one of the world's largest manufacturers of heparin active pharmaceutical ingredients (APIs). Nanjing Kingfriend Pharma is primarily engaged in the research, production, and sales of heparin and related products, including heparin sodium, low molecular weight heparin, heparin calcium, and heparin lithium. Its products are widely used in the fields of cardiovascular and cerebrovascular diseases, oncology, orthopedics, gynecology, and obstetrics.
  China's Active Pharmaceutical Ingredients Industry Analysis
• 2021-08-30
  

  China's International Trade of APIs in the 2020 Epidemic

  In 2020, there are 37 kinds of export single varieties of many APIs and intermediates, with an export value of over 100 million U.S. dollars. Heparin sodium-based bulk medicines topped the list with a total of 1.4 billion US dollars. Its raw materials for nutritional supplements such as coenzyme Q10 and chondroitin sulfate have risen to an export scale of 100 million U.S. dollars. In the field of Antibiotics, Azithromycin, clavulanate potassium series, and chlortetracycline also jumped to 100 million U.S. dollars. Looking at these billion-dollar varieties, most of them are vitamins, nutraceuticals, food additives, antibiotics, antipyretic and Analgesics, and there are not many typical therapeutic drugs. It can be seen that the country with its advantage as an API cannot be proud of itself.
  API international trade chemical drug
• 2019-05-14
  

  Hainan Province: 5 Drugs Apply for Withdrawal due to Cost Increase

  From the "Drug Information of Some Enterprises Applying for Revocation of Networking", we can see that five drugs, Piperazine Ferulate Tablets, Tripibuton Tablets, Lithium Carbonate Tablets, Heparin Sodium Injection and Bupivacaine Hydrochloride Injection, applied for withdrawal because of the rising cost. It is well known that cost increase is a long-term problem faced by many pharmaceutical industry enterprises. Whether the price of raw materials or the cost of manpower, the circulation cost is rising steadily. Under the combined effect of many factors, some varieties of pharmaceutical enterprises are finally unsustainable and have to withdraw from the market.
  medicine